1. Home
  2. SCWO vs CING Comparison

SCWO vs CING Comparison

Compare SCWO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 374Water Inc.

SCWO

374Water Inc.

HOLD

Current Price

$2.51

Market Cap

45.2M

Sector

Utilities

ML Signal

HOLD

CING

Cingulate Inc.

N/A

Current Price

$8.61

Market Cap

74.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCWO
CING
Founded
2021
2012
Country
United States
United States
Employees
27
13
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.2M
74.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCWO
CING
Price
$2.51
$8.61
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.00
AVG Volume (30 Days)
42.0K
303.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5,945.19
N/A
Revenue Next Year
$106.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$3.20
52 Week High
$3.55
$7.92

Technical Indicators

Market Signals
Indicator
SCWO
CING
Relative Strength Index (RSI) 41.72 72.08
Support Level $2.33 $3.58
Resistance Level $3.10 N/A
Average True Range (ATR) 0.21 0.48
MACD -0.05 0.15
Stochastic Oscillator 18.87 95.36

Price Performance

Historical Comparison
SCWO
CING

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: